Sanofi licenses immune disease drugs from startup Earendil

Sanofi licenses immune disease drugs from startup Earendil

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23.

Earendil Labs, Sanofi Ink Global License Deal for Next-Gen Autoimmune Therapies

MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to two bispecific antibodies, H…

Sanofi (SNY) to Issue Annual Dividend of $2.04 on June 12th

Sanofi (NASDAQ:SNY – Get Free Report) declared an annual dividend on Tuesday, April 15th, Wall Street Journal reports. Investors of record on Friday, May 9th will be given a dividend of 2.0369 per share on Thursday, June 12th. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a […]

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory bowel diseases. Sanofi will give $125 million upfront to Earendil Labs for the two experimental ...